Table 4.

Association between drug dose and duration of aspirin and nonaspirin NSAID and adenomatous polyp risk, the TCPS

Adenomatous polyp
NSAID useControlsCasesORa (95% CI)
Never1,6547481.00
Aspirin only use
≤7 doses/wk
<5 y of use4001740.73 (0.59–0.91)
≥5 y of use5432700.77 (0.64–0.94)
>7 doses/wk
<5 y of use32150.69 (0.36–1.31)
≥5 y of use78510.92 (0.61–1.36)
P-interaction0.37
Single agent nonaspirin NSAID
≤7 doses/wk
<5 y of use84270.62 (0.39–0.99)
≥5 y of use121450.85 (0.59–1.24)
>7 doses/wk
<5 y of use92310.60 (0.38–0.93)
≥5 y of use123430.58 (0.40–0.86)
P-interaction0.43
Any combination of NSAID
≤7 doses/wk
<5 y of use30150.68 (0.35–1.33)
≥5 y of use93500.89 (0.61–1.30)
>7 doses/wk
<5 y of use2770.42 (0.18–0.99)
≥5 y of use154530.45 (0.32–0.64)
P-interaction0.83
  • aAdjusted for age, gender, race, family history, education level, BMI, energy intake, smoking status, alcohol use, physical activity, use of hormone replacement therapy, indication for colonoscopy, study site, and year of study enrollment.